New Complementary Combination Therapy for Diabetes: Fixed Dose Basal Insulins and GLP-1 Receptor Agonists

Program Type



1.25 Contact Hour(s)

Release Date

Thursday, January 12, 2017

Offline Date:

Saturday, January 12, 2019

ACPE Expiration Date

Saturday, January 12, 2019

Target Audience




  • Overview

    This activity is designed to educate pharmacists on the role of combination injectable therapy with basal insulin and GLP-1 receptor agonist for patients with diabetes. The activity will include an overview of the ADA and AACE treatment recommendations for patients with type 2 Diabetes.   Participants will understand the pharmacokinetic and pharmacodynamic profiles of currently available basal insulins and GLP-1 agonists.  Data will be presented on the safety and efficacy of basal insulins and GLP-1 agonists administered in combination with a focus on patient selection.  The goal is for pharmacists to counsel patients to improve diabetes self-management and therapeutic outcomes with the use of an emerging fixed combination product.  Case studies will be used to illustrate medication selection, administration, dosing, and adherence management. 


    This recorded activity is a based on a live program that was offered 12/8 Randolph, MA



    The presenter is Dhiren Patel, PharmD, CDE, BC ADM, BCACP; Associate Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA.           

    Dr. Patel is on the speaker’s bureaus of Boehringer Ingelheim, Merck, Novo Nordisk and Sanofi.

    Dr. Patel is also an advisory board member and consultant for AstraZeneca, Novo Nordisk,

    Regeneron and Sanofi


    The reviewer is Regina Ginzburg, PharmD; Associate Clinical Professor, Clinical Health Professions, St. John’s University, NY; Ambulatory Care Clinical Pharmacy Faculty, Mt. Sinai-Beth Israel Family Medicine Residency Program Co-chair, Pharmacy & Therapeutics Committee, Institute for Family Health.  

    Dr. Ginzburg does not have any relevant financial relationships with any commercial interests.


    American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.


    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



    Slide Document:   1 Web Basal_GLP1RAs Combo Patel-FINAL - HANDOUTS.pdf

    Financial Support By

    Novo Nordisk and Sanofi
  • Pharmacist

    Apply current diabetes guidelines in the management of patients with type 2 diabetes with a specific focus on basal insulin therapy and GLP-1 receptor agonists (GLP-1 RAs)
    Compare and contrast the clinical profiles of the different basal insulins and GLP-1 RAs as well as assess their unique PK/PD profiles
    Evaluate current data that relate to fixed ratio combinations (GLP-1 RAs and basal insulin)
    Describe the clinical rationale and expected benefits of using combination therapy with complementary mechanisms of action
    Formulate evidence-based treatment regimens that optimize control of both fasting and postprandial glucose using combination therapy with complementary mechanism of actions

  • Activity Type


    Universal Activity Number

    Pharmacist 0280-0000-17-006-H01-P

    ACPE PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

    In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


843 488 5550 Office

843 488 5554 Fax Email Web

341 Wellness Drive, Myrtle Beach, SC 29579 Address

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyAmerican Health Resources, LLC a subsidiary of PharmCon, Inc.
Developed By: ITB, Inc.